GURU.Markets stock price, segment price, and overall market index valuation
The company's share price REGENXBIO Inc.
REGENXBIO is a biotechnology company pioneering gene therapy. Its stock price reflects both the potential of its own product line and royalties from partners using its proprietary AAV gene delivery technology.
Share prices of companies in the market segment - Dna
REGENXBIO is a biotechnology company pioneering gene therapy. Its NAV Technology platform is used to develop treatments for a wide range of diseases. We classify it as part of the DNA Technologies segment. The chart below illustrates the overall dynamics of this cutting-edge field of medicine.
Broad Market Index - GURU.Markets
REGENXBIO is a leading gene therapy company, holding patents on adeno-associated viral (AAV) vectors used for gene delivery. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with REGENXBIO's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
RGNX - Daily change in the company's share price REGENXBIO Inc.
Shares of REGENXBIO, a gene therapy company, exhibit high volatility, as measured by change_co. This indicator reflects sensitivity to news about clinical trials. This metric is a key component of the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Dna
REGENXBIO Inc. is a biotech company pioneering gene therapy. This chart highlights the sector's extreme volatility. Comparison with RGNX's performance helps to assess it as a high-risk asset whose success depends on its technological platform.
Daily change in the price of a broad market stock, index - GURU.Markets
REGENXBIO is a pioneering company in gene therapy, one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization REGENXBIO Inc.
REGENXBIO's year-over-year performance speaks volumes about the potential of gene therapy. As the owner of a key gene delivery technology (AAV vectors), its market cap has grown over the past 12 months not only due to the success of its own developments but also to the progress of its numerous partners, who pay royalties for the use of its platform, confirming its fundamental value.
Annual dynamics of market capitalization of the market segment - Dna
REGENXBIO Inc. is a leading gene therapy company. Its gene delivery platform (AAV) is licensed to numerous pharmaceutical companies and is used in its own developments. The chart below shows how the market perceives its key technological role and R&D potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
REGENXBIO, a pioneer in gene therapy, is a high-risk, high-potential company. Its stock price is entirely dependent on the results of its clinical trials. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become a new standard in treating rare diseases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization REGENXBIO Inc.
The performance of REGENXBIO, a pioneer in gene therapy, depends on its R&D cycle. The monthly fluctuations on the chart reflect not so much its own revenue, but rather the success of its partners using its gene delivery technology (AAV), and progress in its own clinical program pipeline.
Monthly dynamics of market capitalization of the market segment - Dna
REGENXBIO is a leading biotech company specializing in adeno-associated virus (AAV)-based gene therapy. Their platform enables gene delivery for the treatment of a wide range of diseases. The chart below shows the overall dynamics of the gene therapy sector, one of the most promising, yet complex, areas in medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies with gene therapy platforms are a venture bet on science. The chart below shows investors' overall risk appetite. Is REGENXBIO moving at an extreme amplitude, amplifying market movements?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization REGENXBIO Inc.
REGENXBIO is a pioneer in gene therapy. Its weekly stock price reflects the risks and hopes of biotech. Any news about clinical trials of its NAV platform or FDA decisions triggers extreme fluctuations. This chart shows how science influences the company's value.
Weekly dynamics of market capitalization of the market segment - Dna
REGENXBIO is part of the revolutionary gene therapy sector. The entire segment can experience ups and downs based on major scientific publications or regulatory news that influence how the technology is perceived. This chart shows how REGENXBIO is moving with this wave of innovation and industry sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
REGENXBIO is a pioneer in gene therapy. Shares of companies like this are driven by news of scientific breakthroughs, not GDP reports. The chart clearly demonstrates how often the company's weekly performance diverges from the broader market, demonstrating its immunity to macroeconomic factors.
Market capitalization of the company, segment and market as a whole
RGNX - Market capitalization of the company REGENXBIO Inc.
The REGENXBIO Inc. chart reflects the promise and risks of gene therapy. Its market cap isn't based on current sales, but rather on investors' bets on the potential of its gene delivery platform, NAV. The curve's dynamics show how the market reacts to research and partnership news in this cutting-edge field of medicine.
RGNX - Share of the company's market capitalization REGENXBIO Inc. within the market segment - Dna
REGENXBIO Inc. is a leader in adeno-associated virus (AAV)-based gene therapy, holding stakes both as a developer of its own products and as a licensor of its NAV platform. Its market capitalization reflects the broad application of its technologies in the industry.
Market capitalization of the market segment - Dna
REGENXBIO is a pioneer in gene therapy. How big is this revolutionary arena? The chart below shows the overall market capitalization of the entire DNA technology sector. Its dramatic ups and downs reflect the enormous hopes and scientific risks associated with treating diseases at the genetic level.
Market capitalization of all companies included in a broad market index - GURU.Markets
The REGENXBIO chart shows the market valuation of one of the leading gene therapy platforms. The company's market cap is a bet on the success of its NAV gene delivery technology and its extensive development pipeline. Every jump in the chart reflects clinical data that could change the treatment of many diseases.
Book value capitalization of the company, segment and market as a whole
RGNX - Book value capitalization of the company REGENXBIO Inc.
For REGENXBIO, a gene therapy company, book value is its material foundation: production facilities for vector creation, cutting-edge laboratories, and substantial financial reserves. The chart below shows how this physical and financial capital, which underpins its revolutionary developments, has grown.
RGNX - Share of the company's book capitalization REGENXBIO Inc. within the market segment - Dna
REGENXBIO is a gene therapy pioneer, and its primary asset is a state-of-the-art AAV vector production facility. This GMP-compliant manufacturing complex is the physical key to creating the drugs of the future. The chart shows the company's control over this unique and capital-intensive infrastructure.
Market segment balance sheet capitalization - Dna
REGENXBIO is a gene therapy company. Pharmaceuticals, as the chart shows, are capital-intensive. REGENXBIO owns key intellectual property—a gene delivery platform (AAV)—which it licenses to others, making it relatively asset-light.
Book value of all companies included in the broad market index - GURU.Markets
REGENXBIO's resources include cutting-edge laboratories and manufacturing facilities for the development and production of gene therapy vectors. The chart below shows how the company built its scientific and physical capital to create the drugs of the future.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - REGENXBIO Inc.
REGENXBIO's assets are its laboratories. Its market valuation reflects pure faith in its gene therapy platform and the potential for future drugs. The chart below visualizes the market's hopes and disappointments surrounding its scientific developments.
Market to book capitalization ratio in a market segment - Dna
REGENXBIO is a biotech company specializing in gene therapy. Its valuation is based almost entirely on the potential of its platform and clinical development. The chart shows a significant excess of market capitalization over book value, reflecting high investor expectations.
Market to book capitalization ratio for the market as a whole
REGENXBIO is a pioneer in gene therapy, holding key patents for gene delivery technology. If this chart represents the average valuation, then REGENXBIO is a company whose value lies in its intellectual property. The market values its vast licensing potential and development portfolio, not its laboratories, creating a huge discrepancy between its book value and its overall value.
Debts of the company, segment and market as a whole
RGNX - Company debts REGENXBIO Inc.
REGENXBIO is a pioneer in gene therapy. This chart reflects the financial reality of a clinical-stage biotech company. Raising capital, often through equity or convertible debt, is vital to funding expensive clinical trials and bringing revolutionary but risky treatments to market.
Market segment debts - Dna
REGENXBIO is a biotech company that owns one of the leading adeno-associated virus (AAV) gene therapy platforms. It both develops its own drugs and licenses its technology to other companies. This chart shows how its debt policy reflects its capital needs to fund its clinical trials and build manufacturing facilities.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio REGENXBIO Inc.
REGENXBIO is a biotech company working in the field of gene therapy. Its activities involve lengthy and expensive research. This chart reflects how the company finances its research activities. It shows the extent to which the company relies on debt to conduct clinical trials, which is an indicator of its confidence in the future success of its drugs.
Market segment debt to market segment book capitalization - Dna
REGENXBIO is a pioneer in gene therapy. This chart shows the debt burden in the biotech sector. For companies operating at the cutting edge of science and requiring massive investments in clinical trials, it is an indicator of their ability to fund their research and investor confidence in their platform.
Debt to book value of all companies in the market
REGENXBIO is a biotech company working in the field of gene therapy. Its success depends on the results of years of expensive research. This debt-to-equity ratio chart shows how willing the market is to finance risky projects. This helps assess the company's ability to easily raise funds for its developments.
P/E of the company, segment and market as a whole
P/E - REGENXBIO Inc.
REGENXBIO is a pioneer in gene therapy, holding an extensive patent portfolio for adeno-associated viral (AAV) vectors used for gene delivery. This chart reflects investor confidence in the future of gene therapy. This trend is driven by clinical trial successes in both its own and partner programs.
P/E of the market segment - Dna
REGENXBIO is a pioneer in gene therapy. The company holds patents for its adeno-associated virus (AAV)-based gene delivery platform, which is licensed by many pharmaceutical giants for their drug development. This chart shows the overall valuation of the DNA technology sector, reflecting investor expectations for a revolution in the treatment of genetic diseases.
P/E of the market as a whole
REGENXBIO is a biotech company with one of the leading gene therapy platforms based on the adeno-associated virus (AAV). Its valuation is a bet not only on its own drugs but also on the success of the entire industry, as it receives royalties from other companies. Its valuation is unrelated to the general economic cycles reflected in this chart, but rather depends on scientific breakthroughs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company specializing in gene therapy. Its NAV platform is used by many other companies for gene delivery. This graph reflects expectations for the success of both its own developments and those of its partners. The valuation is a bet on the future of gene therapy and potential royalties from licensed technologies.
%20P%2FE%20REGENXBIO%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-REGENXBIO-Inc.&v=1772659668954 "Chart of the company's future (projected) P/E REGENXBIO Inc.")
Future (projected) P/E of the market segment - Dna
REGENXBIO is a pioneer in gene therapy, developing treatments for rare genetic diseases using adeno-associated viruses. This chart is an indicator of the market's faith in its scientific platform. It compares its highly speculative future revenue expectations with those of the biotech sector, showing its estimated chances of clinical and commercial success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772659668955 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
REGENXBIO is a pioneer in gene therapy, developing drugs to treat rare diseases. This is a risky but potentially disruptive segment of biotechnology. This overall risk appetite chart is critically important, as it determines investors' willingness to fund multi-year, expensive research with uncertain outcomes.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772659668957 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company specializing in gene therapy. Its business model includes both developing its own drugs and licensing its gene delivery platform to other companies. This chart reflects the company's financial performance during the research phase, where revenue depends on successful deals and clinical trial results.
Profit of companies in the market segment - Dna
REGENXBIO is a pioneer in gene therapy, developing gene delivery methods for the treatment of various diseases. The company operates at the forefront of biotechnology, where the risks are high but the potential is enormous. The profitability dynamics in its sector, shown in this chart, often reflect major scientific breakthroughs, regulatory approvals, and investor sentiment.
Overall market profit
REGENXBIO is a pioneer in gene therapy, developing treatments for rare genetic diseases. The company's success in creating breakthrough drugs has the potential not only to transform patients' lives but also to generate enormous economic value. This is an example of how cutting-edge science is driving growth for the entire biotech sector, contributing to overall revenue.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company REGENXBIO Inc.
REGENXBIO is a pioneer in gene therapy. This graph reflects the high but risky expectations for its NAV platform. The company's future profitability depends entirely on the success of clinical trials, regulatory approval, and commercialization of drugs for the treatment of rare genetic diseases.
%20profit%20of%20the%20company%20REGENXBIO%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-REGENXBIO-Inc.&v=1772659668975 "Graph of future (projected) profit of the company REGENXBIO Inc.")
Future (predicted) profit of companies in the market segment - Dna
REGENXBIO Inc. is a pioneer in gene therapy, developing treatments based on the adeno-associated virus (AAV). This chart illustrates profitability projections for the biotech sector. It helps assess the level of expectations for the company's revolutionary gene therapy technology within the context of the industry as a whole.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772659668982 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
The dynamics in this chart reflect expectations for a biotech company specializing in gene therapy. REGENXBIO's profit forecast depends on the success of its clinical programs and revenue from licensing agreements with other pharmaceutical companies. Trial results and regulatory decisions are key events influencing the trajectory.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772659668984 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - REGENXBIO Inc.
REGENXBIO, a gene therapy company, has irregular revenue from licensing fees. This chart shows that its valuation is based not on current sales, but on the potential of its technology platform. Investors evaluate future revenue streams from developments in various stages of clinical trials.
P/S market segment - Dna
REGENXBIO is a leader in gene therapy, developing AAV technologies. The company's revenue is generated through partnerships and licensing agreements. This chart shows the average valuation in the biotech sector, reflecting how investors assess REGENXBIO's future revenue potential from its breakthrough scientific platform compared to other biotech companies.
P/S of the market as a whole
REGENXBIO is a biotech company that operates a gene therapy platform. Its business model is based on licensing its technology to other pharmaceutical companies and developing its own drugs. This chart shows the average market revenue estimate, allowing one to estimate the premium investors are willing to pay for this breakthrough technology and the potential for future royalty income.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company REGENXBIO Inc.
REGENXBIO is a biotech company specializing in gene therapy. Its NAV Technology platform is licensed to other companies, generating royalty revenue, and is used for its own development. This chart shows how investors estimate future revenue from licensing agreements and the potential success of its own drugs in development.
%20P%2FS%20REGENXBIO%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-REGENXBIO-Inc.&v=1772659669026 "The graph of the company's future (projected) P/S REGENXBIO Inc.")
Future (projected) P/S of the market segment - Dna
REGENXBIO is a pioneer in adeno-associated virus (AAV)-based gene therapy. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. This valuation reflects investor confidence in its NAV Technology platform and its extensive portfolio of licensed and proprietary clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772659669042 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
REGENXBIO is a biotech company specializing in gene therapy. Its business is at the cutting edge of science. The success of its clinical trials and the potential launch of new drugs could create entirely new revenue streams. This graph also reflects expectations for breakthroughs that could transform medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772659669044 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales REGENXBIO Inc.
REGENXBIO is a pioneer in gene therapy, developing and licensing its NAV Technology platform for gene delivery. The company's revenue comes from royalties and payments from partners who use its technology to create drugs. This chart shows how research and development and partnerships translate into real cash flow.
Sales of companies in the market segment - Dna
REGENXBIO Inc. is a pioneer in gene therapy, developing a platform for delivering therapeutic genes using adeno-associated vectors (AAVs). The company's technology has the potential to form the basis for treating a wide range of diseases. This chart reflects overall sales in the sector, demonstrating the potential and growth of the gene therapy market, where REGENXBIO aims to become a technology leader.
Overall market sales
REGENXBIO is a pioneer in gene therapy, developing a platform for delivering therapeutic genes to treat various diseases. This overall economic activity graph for REGENXBIO is important because it impacts the investment climate in biotechnology. A healthy economy facilitates the influx of capital into long-term, high-risk scientific projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company REGENXBIO Inc.
REGENXBIO is a pioneer in gene therapy, developing treatments for rare genetic diseases. The company's future revenue depends on regulatory approvals and the success of clinical trials. This graph reflects analysts' confidence in the potential of its technology platform and its ability to create revolutionary drugs that can change patients' lives.
%20sales%20of%20the%20company%20REGENXBIO%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-REGENXBIO-Inc.&v=1772659669068 "Schedule of future (projected) sales of the company REGENXBIO Inc.")
Future (projected) sales of companies in the market segment - Dna
REGENXBIO Inc. is a biotechnology company specializing in gene therapy. This chart shows projected revenues for the entire biotechnology sector. It reflects overall expectations for investment in innovative treatments, which is an important backdrop for assessing the potential of REGENXBIO's gene therapy platform and its partner programs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772659669082 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
REGENXBIO is a biotechnology company specializing in gene therapy. Its success depends on the results of clinical trials and the ability of the healthcare system to pay for innovative treatments. This graph, reflecting the state of the economy, is important in the long term, as economic growth and stability allow governments and insurance companies to finance expensive, cutting-edge therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772659669086 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality REGENXBIO Inc.
REGENXBIO is a biotech company working in the field of gene therapy. This chart reflects its journey from research to commercialization. Profitability at this stage is often negative due to the massive investment in clinical trials. This metric illustrates how the company manages its finances while awaiting approval of its drugs.
Market segment marginality - Dna
REGENXBIO is a pioneer in gene therapy, developing potentially revolutionary treatments. For a biotech company at the cutting edge of science, its operational structure reflects its stage of development. This chart shows how the company manages its enormous research expenditures compared to its peers on the path to commercialization of its technologies.
Market marginality as a whole
REGENXBIO is a pioneer in gene therapy, developing potentially curative treatments for rare diseases. The company's profitability depends on the success of its clinical trials and the commercialization of its platform. This total market return chart serves as a contrast to the biotech sector, where scientific breakthroughs, not general economic trends, determine a company's future value.
Employees in the company, segment and market as a whole
Number of employees in the company REGENXBIO Inc.
REGENXBIO is a pioneer in gene therapy, developing a platform for delivering therapeutic genes using AAV vectors. This chart illustrates the size of its team of scientists and clinicians. This growth directly reflects progress in research, the launch of new clinical programs, and investments in building manufacturing facilities for this complex technology.
Share of the company's employees REGENXBIO Inc. within the market segment - Dna
This figure reflects REGENXBIO's unique position in the field of gene therapy. The company's workforce in this cutting-edge biotech sector is focused on the development and licensing of its adeno-associated viral vector (AAV) platform. This team of scientists creates gene delivery vehicles used in both its own and partner programs.
Number of employees in the market segment - Dna
REGENXBIO is a biotechnology company pioneering adeno-associated vector (AAV)-based gene therapy. Its platform has the potential to become the basis for treating a wide range of diseases. This graph illustrates the growth of cutting-edge science, where REGENXBIO is driving demand for geneticists and molecular biologists—the specialists who are creating the medicine of the future.
Number of employees in the market as a whole
REGENXBIO Inc. is a pioneer in gene therapy. Its value is determined by scientific breakthroughs, not the labor market, as reflected in this chart. The company operates at the forefront of medicine, creating life-changing treatments, and its success is unrelated to traditional economic indicators.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company REGENXBIO Inc. (RGNX)
REGENXBIO is a pioneer in gene therapy, holding a vast portfolio of patents for AAV vectors. This chart clearly demonstrates the value of its intellectual property. The astronomical market capitalization per employee suggests that the market values not the company's headcount, but the potential for licensing fees from the entire industry using its fundamental technology.
%20of%20the%20company%20REGENXBIO%20Inc.%20(RGNX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-REGENXBIO-Inc.-RGNX&v=1772659669153 "Chart of market capitalization per employee (in thousands of dollars) of the company REGENXBIO Inc. (RGNX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
REGENXBIO is a pioneer in gene therapy, where the company's value is determined by its scientific platform. This chart shows the market's confidence in the developments being developed by its team of scientists. The high market capitalization per employee is typical for biotech and reflects the enormous potential of future drugs.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772659669155 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
REGENXBIO Inc. is a biotech company specializing in gene therapy. This chart shows an extremely high NAV per employee. This reflects the enormous potential of its technology platform. Investors evaluate not current revenue, but the future value of the intellectual property created by a small team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772659669159 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company REGENXBIO Inc. (RGNX)
REGENXBIO is a biotech company specializing in gene therapy. They own the NAV platform for vector-based gene delivery (AAV). This is a research-intensive business. This chart shows how successful the company is in monetizing its platform—either through licensing (like Novartis' Zolgensma) or through developing its own drugs.
%20Chart%20REGENXBIO%20Inc.%20(RGNX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-REGENXBIO-Inc.-RGNX&v=1772659669200 "Company Profit Per Employee (in thousands of dollars) Chart REGENXBIO Inc. (RGNX)")
Profit per employee (in thousands of dollars) in the market segment - Dna
REGENXBIO is a biotech company focused on gene therapy using AAV vectors. In biotech, profits are generated not by mass production, but by scientific breakthroughs. This chart shows how effectively the company monetizes its intellectual property. It serves as a benchmark for assessing how successfully REGENXBIO's team of scientists and managers advances its developments toward commercialization compared to competitors.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772659669244 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
REGENXBIO (RGNX) is a biotech company specializing in gene therapy using adeno-associated viral (AAV) vectors. During the R&D stage, this indicator is almost always negative, as the company incurs enormous expenses on scientists and testing. This graph is an indicator of success: if it turns positive, it could indicate drug approval or large advance payments from partners, monetizing the researchers' work.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772659669256 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee REGENXBIO Inc. (RGNX)
REGENXBIO is a pioneer in gene therapy. This chart illustrates the biotech company's intellectual property-based model. High revenue per employee is achieved by licensing its NAV platform to other pharmaceutical companies, allowing them to monetize the technology even before launching their own products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-REGENXBIO-Inc.-RGNX&v=1772659669279 "Sales chart per company employee REGENXBIO Inc. (RGNX)")
Sales per employee in the market segment - Dna
REGENXBIO is a biotech company specializing in gene therapy using its NAV platform. This chart shows the average revenue per employee in this segment. For biotech companies in the R&D stage, revenue may be irregular (partnerships, licensing). This metric compares their performance with that of competitors also working at the cutting edge of science.
Sales per employee for the market as a whole
REGENXBIO is a biotech company that owns a key platform (NAV) for gene therapy. Rather than producing drugs, they license their gene delivery technology to other pharmaceutical companies (such as Novartis). This reflects their R&D model: a small team of scientists owns the intellectual property, which generates royalties.
Short shares by company, segment and market as a whole
Shares shorted by company REGENXBIO Inc. (RGNX)
REGENXBIO is a biotech company specializing in gene therapy using AAV vectors. This chart shows the stakes of those who doubt its R&D. Bears point to the high competition in gene therapy, the risk of clinical trial failure, and the enormous costs required to bring products to market with no guarantee of success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-REGENXBIO-Inc.-RGNX&v=1772659669317 "Short Shares Chart for the Company REGENXBIO Inc. (RGNX)")
Shares shorted by market segment - Dna
REGENXBIO is a biotech company focused on gene therapy. It owns the NAV gene delivery platform, which it licenses to other companies. This chart reflects the overall sentiment in the sector. It reflects the high investor skepticism toward the entire biotech industry, with investors anticipating clinical trial failures or funding challenges in the DNA technology sector.
Shares shorted by the overall market
REGENXBIO is a clinical-stage biotech company specializing in gene therapy. Its survival depends on access to funding. When this market pessimism indicator rises, the window for raising capital slams shut. Investors panic and flee unprofitable, speculative ventures like RGNX, fearing they'll run out of money.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator REGENXBIO Inc. (RGNX)
REGENXBIO (RGNX) is a biotech company pioneering gene therapy. They hold extensive patents for their gene delivery platform (AAV vectors) and are developing their own drugs. This chart measures hype. It shows "overbought" (above 70) due to news of R&D successes (either their own or their partners') or "oversold" (below 30) due to trial failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-REGENXBIO-Inc.-RGNX&v=1772659669351 "RSI 14 indicator chart for the company's stock REGENXBIO Inc. (RGNX)")
RSI 14 Market Segment - Dna
REGENXBIO (RGNX) is a pioneer in gene therapy. They own a key platform (AAV) for gene delivery, which they license to others, and are also developing their own drugs. This chart tracks the collective sentiment in the DNA/Genomic Technologies sector. It shows when the entire industry is overheated by hype surrounding breakthroughs or oversold by setbacks.
RSI 14 for the overall market
REGENXBIO (RGNX), a gene therapy company. This chart is its lifeline. Its business is pure R&D. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and RGNX risks running out of funds for its breakthrough, but expensive, research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RGNX (REGENXBIO Inc.)
REGENXBIO (RGNX) is a pioneer in gene therapy. The company holds an extensive patent portfolio for adeno-associated viral (AAV) vectors used for gene delivery. This chart shows the average Wall Street forecast. It reflects analysts' assessments of the value of their platform (NAV technology) and the success of their own clinical programs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RGNX-REGENXBIO-Inc.&v=1772659669378 "A chart showing analyst consensus forecasts for the expected stock price. RGNX (REGENXBIO Inc.)")
The difference between the consensus estimate and the actual stock price RGNX (REGENXBIO Inc.)
REGENXBIO is a gene therapy pioneer. The company owns one of the key platforms (NAV Technology) for gene delivery, which it licenses to others, and also develops its own drugs. This chart measures the gap between the current price and the consensus target price. It shows how much confidence experts have in their technology and development pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RGNX-REGENXBIO-Inc.&v=1772659669386 "A chart showing the difference between the consensus forecast and the actual stock price. RGNX (REGENXBIO Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
REGENXBIO (RGNX) is a pioneer in gene therapy, possessing a key "delivery system" (NAV) for gene correction. The company both develops drugs itself and licenses its technology. This chart shows analysts' overall expectations for the entire DNA technology sector. It reflects whether experts believe gene therapy will be commercially successful.
Analysts' consensus forecast for the overall market share price
REGENXBIO (RGNX) is a biotech that owns a key platform (NAV Technology) for delivering gene therapy. They license it to pharma. This chart of overall market sentiment is important. Optimism = biotechs easily raise money and spend it on R&D (by licensing the RGNX platform). Pessimism = venture winter = R&D freeze.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index REGENXBIO Inc.
REGENXBIO (RGNX) is a leading gene therapy company. While they don't develop all their drugs themselves, they own one of the key platforms (NAV vectors) for gene delivery, which they license to giants like Novartis. This chart is a hybrid, weighing their in-house R&D pipeline against their high-margin royalty portfolio from their numerous licensing deals.
AKIMA Market Segment Index - Dna
REGENXBIO (RGNX) is a biotech pioneer in gene therapy; the company owns one of the most important R&D platforms (NAV Technology) for delivery (AAV vectors), which it licenses to the entire pharmaceutical industry (Novartis, Zolgensma). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this unique (fintech R&D) model (RGNX) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
REGENXBIO is a biotech company, a leader in AAV gene therapy. Its NAV platform is used in Zolgensma and its own developments (eye and muscle). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative company, which owns key IP, compares to overall economic trends.
